Market openADR
Ascendis Pharma/$ASND
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Trading on
Industry
Biotechnology
Headquarters
Hellerup, Denmark
Employees
879
Website
Ascendis Pharma Metrics
BasicAdvanced
$7.7B
-
-$7.85
0.65
-
Price and volume
Market cap
$7.7B
Beta
0.65
52-week high
$161.00
52-week low
$111.09
Average daily volume
419K
Financial strength
Current ratio
1.161
Quick ratio
0.806
Long term debt to equity
-348.263
Total debt to equity
-810.38
Interest coverage (TTM)
-2.88%
Management effectiveness
Return on assets (TTM)
-20.07%
Return on equity (TTM)
499.54%
Valuation
Price to revenue (TTM)
21.281
Price to book
-78.72
Price to tangible book (TTM)
-75.54
Price to free cash flow (TTM)
-26.548
Growth
Revenue change (TTM)
115.54%
Earnings per share change (TTM)
-30.33%
3-year revenue growth (CAGR)
357.65%
3-year earnings per share growth (CAGR)
-1.09%
What the Analysts think about Ascendis Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Ascendis Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ascendis Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ascendis Pharma News
AllArticlesVideos
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·2 weeks ago
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·3 weeks ago
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $7.7B as of January 27, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of January 27, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of January 27, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.